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Spray dryingAbstract The use of drug powders containing micronized drug particles has been increasing in sev-
eral pharmaceutical dosage forms to overcome the dissolution and bioavailability problems. Most
of the newly developed drugs are poorly water soluble which limits dissolution rate and bioavail-
ability. The dissolution rate can be enhanced by micronization of the drug particles. The properties
of the micronized drug substance such as particle size, size distribution, shape, surface properties,
and agglomeration behaviour and powder ﬂow are affected by the type of micronization technique
used. Mechanical communition, spray drying and supercritical ﬂuid (SCF) technology are the most
commonly employed techniques for production of micronized drug particles but the characteristics
of the resulting drug product cannot be controlled using these techniques. Hence, a newer technique
called in situ micronization is developed in order to overcome the limitations associated with the
other techniques. This review summarizes the existing knowledge on in situ micronization tech-
niques. The properties of the resulting drug substance obtained by in situ micronization were also
compared.
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In the recent years, it is estimated that 90% of the New Chem-
ical Entities (NCEs) are poorly water soluble compounds
which come under Biopharmaceutical classiﬁcation system
(BCS) class II or class IV (Filippos and Yunhui, 2008).
According to BCS, dissolution is the rate limiting factor for
the drug absorption rate of both class II and class IV com-
pounds which result in poor bioavailability. Owing to their
low poor water solubility and bioavailability, several potential
drugs are abandoned in pharmacological screenings (Robin-
son, 1993; Rasenack and Muller, 2002a). It is a well-known
major hurdle for the formulators to handle such poorly water
soluble compounds. The chemical and physical properties of
the poorly soluble compounds can be optimized to improve
oral bioavailability of water insoluble compounds. Various
formulation strategies have been reported to improve solubil-
ity and dissolution rate of poorly water soluble drugs such as
inclusion of complexation with cyclodextrins, solid dispersion,
salt formation, particle size reduction, use of surfactants,
cosolvency, hydrotrophy, etc. Amongst above mentioned
methods, the most reliable technique to improve the dissolu-
tion rate is micronization (Rasenack and Muller, 2004; Jalay,
2011).
Micronization is a term used to describe size reduction tech-
nique where the resulting particle size distribution is less than
10 l. Since the morphology of particles, particle size and size
distribution produced in different industries are usually not
appropriate for the subsequent use of such materials; particle
design has been gaining importance in manufacturing ad-
vanced coating materials, microsensors, polymers, pharmaceu-
ticals, and many other chemicals. The present article
thoroughly reviews about in situmicronization as a novel micr-
onization technique.
2. In-situ micronization
In-situ micronization is a novel particle engineering technique
where micron sized crystals are obtained during its production
itself without the need for any further particle size reduction
(Rasenack and Muller, 2002a; Rasenack et al., 2002a). In
contrast to other techniques where external processing
conditions like mechanical force, temperature and pressureare required, the drug is obtained in micron size during the
crystal formation. Hence this technique is described as in situ
micronization. Each and every aspect of in situ micronization
technique is discussed in the following sections.
2.1. Equipment and processing conditions
In-situ micronization is one of the easiest methods to produce
microcrystals which is a one-step process that requires
common equipment (Rasenack et al., 2002a, 2003) whereas
other micronization techniques like milling, spray drying,
and supercritical ﬂuid (SCF) require specialized containment
facilities that pose typical issues which include expensive
processing conditions, intensive labour, loss of material, dust
explosion risks etc.
Spray drying is a comprehensive technique where it requires
high shear rates and specialized atomizer for micronization of
drug substances where the size of the atomizer determines the
particle size of the resulting drug substance (Chiou and Lang-
rish, 2008; Sunday and Simon, 2006). It requires more process-
ing time ranging from several hours to days. Whereas in SCF
technology supercritical carbondioxide (SCO2) is used which
requires specialized conditions like temperature at 304.2 K
and pressure at 7.38 MPa to maintain CO2 at supercritical con-
ditions (Masoud and Sima, 2007; Pasquali et al., 2006; Rase-
nack and Muller, 2004; Deelip et al., 2010). It requires
supersonic speeds for rapid expansion of SCO2. SCF requires
less processing time for micronization but the major drawback
of using SCFs is the limited number of drugs that can be pro-
cessed in super critical CO2. These techniques lead to increased
cost of both the drug development process as well as the ﬁnal
drug product. In-situ micronization technique is beneﬁcial in
these aspects as it does not require any external processing
conditions except mild agitation using magnetic stirrer (Rase-
nack and Muller, 2002a) and the processing time is less
compared to the other techniques.
2.2. Particle size and size distribution
According to the Noyes–Whitney postulations, the administra-
tion of a drug in micron size is a prominent method to improve
bioavailability of poorly water soluble drug substances (Kawa-
shima, 2001; Chaumeil, 1998) which can increase solubility and
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very important characteristics which have signiﬁcant effects
on ﬂowability, dissolution properties and release kinetics
(Mullarney and Leyva, 2009; Miranda et al., 2007; Koennings
et al., 2007). Milling, spray drying and SCF technologies are
mostly employed micronization techniques which can enhance
the solubility and dissolution rates. Although these techniques
can produce particles of micron size, there will be a non-
homogenous particle size distribution due to the agglomera-
tion of the particles (Yohei et al., 2011) which decreases the
surface available for dissolution (Irngartinger et al., 2004; Sun-
day and Simon, 2006). Whereas, in situ micronization tech-
nique (Kim et al., 2003; Varshosaz et al., 2008) was proved
as novel technique which has produced micron size crystals
with homogenous particle size distribution as it was observed
in case of gliclazide micocrystals. Further, particle size can
be controlled in this technique because agitation is employed
in this technique. Rasenack and Muller optimized the crystal
properties of ibuprofen using in situ micronization technique
which diminished the agglomerative tendency of ibuprofen
crystals (Rasenack and Muller, 2002b).
2.3. Surface modiﬁcation and stability enhancement
Formation of amorphous regions as in case of milling, spray
drying and SCF technology is undesirable because they lead
to poor stability. Micronization alone, however, can lead to
many processing problems related to poor ﬂow and dispersion
properties. Mechanical activation of the drug substance occurs
due to milling which may lead to unstable product which is evi-
denced from the reduced physical stability of salbutamol sul-
phate (Brodka et al., 2003) and simvastatin (Fang et al., 2009).
It is therefore important to micronize a drug substance
along with simultaneous surface modiﬁcation. In-situ micron-
ization is such a technique where microcrystallization and sur-
face modiﬁcation can be done using hydrophilic polymers
which act as stabilizing agents in order to enhance wetting
properties and stability of the microcrystals. Further, the stabi-
lizing agents prevent the crystal growth behaviour of the
microcrystals (Schott, 1985; Rasenack and Muller, 2002a).
The type of stabilizing agent had a signiﬁcant effect on
morphology of particles and hence on their ﬂow (Roya
et al., 2009). Stabilizing agents possess high afﬁnity towards
the newly formed hydrophobic surface which sterically stabi-
lizes the microcrystals against the crystal growth by forming
a protective layer around the microcrystals (Schott, 1985). Sta-
bilizing agent covers the hydrophobic surface which results in
microcrystals with low adhesivity, low agglomeration, and low
electrostatic behaviour that would improve powder ﬂow
although ﬁne particle fraction is increased (Rasenack et al.,
2003). On other hand, the selection and use of effective stabi-
lizer are important tasks to obtain high drug load in powders
(Rasenack and Muller, 2004).
Intensive investigation has been carried out in the recent past
to evaluate the ability of stabilizing agents viz. dextran, gelatin,
hydroxyethyl starch (HES), hydroxyethyl cellulose (HEC), hy-
droxyl propyl cellulose (HPC), methyl cellulose (MC), methyl
hydroxy ethyl cellulose (MHEC), hydroxyl propyl methyl cellu-
lose (HPMC), sodium carboxy methyl cellulose (NaCMC), so-
dium alginate, pectin, polyvinyl alcohol (PVA) polyvinyl
pyrrolidone (PVP) and polyethylene glycols (PEG). The draw-ings of those ﬁndings, say that the stabilizing agent with more
polar substituted cellulose ethers such as dextran, PEG and
HES are not able to show sufﬁcient stabilization on ibuprofen
crystals (Rasenack and Muller, 2002b; Bunyan et al., 1991).
This could be due to the poor afﬁnity of the polar substituents
towards the newly formed hydrophobic crystal surface. In con-
trast, MC, MHEC, HPMC and PVA possess alkyl substituents
which have more afﬁnity towards the hydrophobic crystal sur-
face and stabilized the drug substance (Chang and Gray, 1978;
Daniels and Barta, 1994; Rasenack and Muller, 2002a). Due to
the surface adsorption of these alkyl substituted cellulose ethers,
the interfacial tension was found low. Further, it was concluded
that HPMC showed better stability compared to MC, MHEC
because of higher degree of alkyl substitution. It was also assim-
ilated that, after 60 and 120 min precipitation of drug substance
has not shown any signiﬁcant increase in particle size (Rasenack
et al., 2003). Thus, stability of the resultant product was based
on surface modiﬁcation by the type of stabilizing agent. The
amount of stabilizing agent has no effect on the particle size.
The use of higher amounts of HPMC did not result in smaller
itraconazole particles (Rasenack and Muller, 2002a). Based
on this, it is concluded that the choice of stabilizer is speciﬁc
to each drug candidate.
Anti-inﬂammatory drugs like beclomethasone-17,21-dipro-
pionate (BDP), betamethasone-17-valerate (BV), triamcino-
lone acetonide, budesonide and prednisolone were
micronized by controlled crystallization followed by drying
using HPMC as stabilizing agents. The respirable fraction
was increased compared to jet milled products. The side effects
like drug deposition in the throat can be avoided using this
technique (Rasenack et al., 2002a; Varshosaz et al., 2008).
2.4. Crystalline habit
The main reason to select crystalline state of drugs is their ther-
modynamic instability in amorphous state. Disruption of crys-
tal lattice occurs due to high energy input in case of milling and
spray drying which gives thermodynamically activated amor-
phous surface which further convert back to crystalline mate-
rial upon storage (Rasenack et al., 2004; Ward and Schultz,
1995; Ogura and Sobue, 1970).
Crystal modiﬁcation affects agglomeration tendency, ﬂow
properties and dissolution behaviour (Gordon and Chowhan,
1990; Rasenack and Muller, 2002b). Employing in situ micron-
ization has converted the rod shaped gliclazide (Varshosaz
et al., 2008) and glibenclamide crystals (Amal et al., 2012) to
cube shaped crystals with enhanced dissolution properties with-
out any polymorphic changes. Spherical shaped crystals with
enhanced ﬂow properties were observed in case of betametha-
sone-17-valerate (Rasenack et al., 2002a). Enhanced crystal
properties were observed for disodium cromoglycate (DSCG)
when compared to jet milled product (Steckel et al., 2003).
2.5. Flow properties
Powders having a particle size <10 l are highly cohesive and
oppose ﬂow under gravity. The powder ﬂow properties are un-
able to control in traditional micronization techniques such as
milling and spray drying. Even simple micronization, was not
promising in increase of effective surface area and resulted in
no effect on dissolution rate (Kendall and Stainton, 2001; Xi
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has greater tendency to agglomerate which subsequently gives
rise to increased electrostatic charges and poor ﬂowability
which affect processing and handling (Perrut et al., 2005a,b;
Liversidge and Cundy, 1995; De Villiers, 1995, 1996).
Micronization by milling and spray drying leads to amor-
phous substances (White and Cakebread, 1966; Chiou and
Langrish, 2008) which lead to poor ﬂow and deposition of
powders on the walls of spray dryer (Adhikari et al., 2003;
Bhandari et al., 1997; Chan and Chew, 2003). The number
and location of amorphous regions are difﬁcult to control. Re-
duced cohesiveness in micronized materials can be achieved by
crystallization. In-situ micronization gives more crystalline
substances that can reduce the cohesiveness and can improve
the ﬂow properties (Rasenack and Muller, 2002b). The ﬂow-
ability and dispersibility of the in situ micronized powder were
improved effectively and used in pulmonary drug delivery.
Flow properties of ﬂuticasone-17-propionate, an anti-inﬂam-
matory drug used in chronic obstructive pulmonary disease
(COPD) was enhanced using in situ micronization technique
compared to jet-milled product (Steckel et al., 2003).
2.6. Dissolution enhancement
Drugs with low solubility lead to poor dissolution rate which
further leads to issues such as non-linear pharmacokinetics, in-
tra and inter-individual absorption variability (Yohei et al.,
2011). Micronization of poorly water soluble drugs leads to in-
creased absolute surface area but the effective surface area re-
quired for wetting is less which leads to ﬂotation as could be
observed from dry milling (Rasenack et al., 2004). Due to this
reason, dissolution rate of the milled products was not in-
creased as it is expected from the Noyes-Whitney equation
(Sharma et al., 2009; Leena and Jouni, 2010). Spray-drying
technique is easy to handle, if water-soluble drugs are to be
micronized. However, in the case of poorly soluble drugs, or-
ganic liquids are required that necessitate high machine expen-
diture (Reinhard, 2008). SCF technology is suitable for
dissolution enhancement of drugs that are soluble in SCO2 like
lysozyme particles (Young et al., 1999), nifedipine and lido-
caine (Perrut et al., 2005a,b). Drugs that are not soluble in
SCO2 are difﬁcult to process through SCF technology. In-situ
micronization can be used in such cases to enhance ﬂow prop-
erties and dissolution rate. When a hydrophobic substance is
micronized, a hydrophobic surface is formed. As hydrophilic
polymers are used as stabilizing agents in case of in situ micr-
onization technique, they can enhance the wetting properties
and dissolution rate. Surface adsorption of hydrophilic poly-
mers like HPMC and MHEC show enhanced wetting proper-
ties which can there by enhance dissolution rate. Dissolution
rate was enhanced for gliclazide, betamethazone, prednisolone,
budesonide, itraconazole and ketoconazole by in situ micron-
ization technique using HPMC (Varshosaz et al., 2008; Rase-
nack et al., 2002a,b).
2.7. Drug degradation behaviour
There is less chance for physical or chemical degradation in
case of in situ micronization technique as external processing
conditions like high shear rates, temperature or pressure are
not required. Whereas in other techniques like the drug degra-dation chances are more because of high shear forces and rapid
decompression (expansion) in case of milling, spray drying and
SCF technology (Snow et al., 1984; Sunday and Simon, 2006;
Abhijit and Patravale, 2004). These techniques produce more
amorphous particles which are rapidly cleared from systemic
circulation due to enzymatic degradation which is due to their
high reactivity (Lee et al., 2005).
2.8. Methods of preparation
Solvent change method and pH shift method are to be used in
in situ micronization technique (Rasenack and Muller, 2002c).
These methods are proved to be promising to enhance ﬂow
properties, dissolution rate and stability of poorly water solu-
ble substances and to enhance ﬂow properties of water-soluble
drugs (Steckel et al., 2003).
2.8.1. Solvent change method
This technique involves precipitation in the presence of protec-
tive hydrophilic polymers followed by drying. Solvent change
method is effectively applicable to both water soluble and
insoluble drugs. The non-solvent is used as precipitating med-
ium. For poorly water soluble drugs, drug is to be dissolved in
suitable organic solvent. The majority of stabilizing agents are
usually hydrophilic polymers, are to be dissolved in aqueous
solvent which acts as non-solvent to the drug. Both the solu-
tions are to be mixed batch-wise in 1:4 (Rasenack et al.,
2004) or 1:8 ratios (Steckel et al., 2003). The resulting micro-
crystals are to be dried using oven or by spray dryer (Rasenack
et al., 2003). Spray dryer is used only to dry the pre-formed
particles but not for size reduction (Rasenack et al., 2003; Stec-
kel et al., 2003). The stabilizers present in aqueous phase ad-
sorb on the nucleated drug particles hindering the crystal
growth.
Gliclazide microcrystals, betamethasone, budesonide and
prednisolone were prepared by solvent change method using
HPMC as stabilizing agent which showed an enhanced disso-
lution rate (Rasenack et al., 2003; Varshosaz et al., 2008).
DSCG microcrystals were prepared by batch-wise mixing
of the drug solution in isopropyl alcohol and aqueous
HPMC solution at 1:8 ratio to enhance the ﬂow properties
and aerodynamic behaviour of DSCG (Steckel et al.,
2003). The same procedure was used to prepare ibuprofen
microcrystals by batch-wise mixing of drug solution in iso-
propyl alcohol and HPMC aqueous solution in 1:4 ratio
(Rasenack et al., 2004).
2.8.2. pH shift method
pH shift method is well suitable for drugs with pH dependent
solubility. In this method pH of the system needs to be altered
slowly from basic to acidic or vice versa. 0.1 N NaOH and
0.1 N HCl are commonly used to alter pH. A high speed
homogenizer with a speed of 26,000 rpm is employed to pre-
vent aggregation while altering pH from basic to acidic or vice
versa within a time gap of 5 min for effective microcrystalliza-
tion (Roya et al., 2009).
Gliclazide microcrystals were prepared by pH shift method
using PEG, CMC, PVP and pluronics and freeze dried. It was
observed that freeze drying has no effect on particle size
distribution (Roya et al., 2009; Mauludin et al., 2009) and an
enhanced dissolution rate was observed compared to untreated
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pared by pH shift method using zinc acetate to alter the pH
which also acts as stabilizer. Plate shaped microcrystals were
obtained with an enhanced dissolution rate (Sung et al.,
2003; Gibson, 2001).
2.9. Merits
 Critical effects resulting from milling processes can be
avoided as all crystals are naturally grown.
 The microcrystals produced by this technique are in situ sur-
face modiﬁed due to adsorption of hydrophilic polymers
which enhances wettability.
 The in situ micronized crystals form homogeneous suspen-
sions with less sedimentation due to the small particle size
and hydrophilized surface which can be easily dispersible
(Steckel et al., 2003).
 The aerodynamic behaviour can be improved to improve
the powder ﬂow with increased ﬁne particle fraction.
 It is also applicable for the pulmonary use. Compared to
the jet-milled drugs, the respirable fraction of these micro-
crystals is increased which can prevent the side effects like
drug deposition in throat (Steckel et al., 2003; Rasenack
et al., 2003; Rasenack et al., 2002a,b).
 In-situ micronization gives microcrystals with high drug
load compared to other techniques like spray drying where
yield is 20–50% (Labrude et al., 1989; Sunday and Simon,
2006).
 Evaporative precipitation into aqueous solution (EPAS) is
also a precipitation technique but it requires high pressure
for the evaporation of organic solvent from the solution
whereas in situ micronization does not require any external
forces (Chen et al., 2002; Sarkari et al., 2002).
2.10. Limitations
 In case of rapid solvent change process; the afﬁnity of the
hydrophilic polymer towards the newly formed crystal sur-
face, partition coefﬁcient of drug between the solvent and
non-solvent limit the formation of microcrystals (Rasenack
et al., 2002a,b).
 In-situ micronization of hydrophilic drugs may lead to for-
mation of larger particles (Rasenack et al., 2002b).
 Controlling of crystal size is not an easy task in this method.
2.11. Applications
The microcrystals prepared by this technique can be used in li-
quid preparations without any crystal growth with less sedi-
mentation rate which can be redispersed easily.
These microcrystals can be incorporated into suitable semi-
solid dosage forms for therapeutic and cosmetic purposes
(Rasenack and Muller, 2002c).
In-situ micronization technique is well suitable for pulmon-
ary drug delivery systems which require a particle size around
5 l. Microparticles obtained by in situ micronization can be
formulated into dry powder inhalers (DPI) or aerosols because
of improved aerodynamic behaviour (Steckel et al., 2003).
DSCG microcrystals were prepared by in situ micronizationtechnique with enhanced respirable fraction compared to jet-
milled DSCG to formulate into DPIs (Rasenack et al., 2004).
They can be used as solids in solid dosage forms such as
capsules, tablets or pills. They are also suitable to formulate
as parenterals.
3. Conclusion
Althoughmanyother techniques are available formicronization
like spray drying and supercritical ﬂuid technology, they are
more complicated and require high processing conditions that
make the resultant product highly expensive. Furthermore the
stability of particles obtained by these techniques is less due to
the formation of amorphous surfaces which limits their applica-
tion in pharmaceutical industry. In-situ micronization is a new
class ofmicronization technique which can overcome the limita-
tions associated with the other techniques. It can be able to pro-
ducemicrocrystals of homogenousparticle size distributionwith
improved ﬂowproperties, dissolution behaviour and stability. It
reduces the cost of the ﬁnal product because of simple process in-
volved in the production ofmicrocrystals. Further studies on the
choice of stabilizing agents and the scale up techniques are re-
quired for the effective use of this technique in pharmaceutical
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